Please assess the completion status of the following clinical trial:

Trial Title: Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with age above 18 years old~* Patient with diagnosis of ulcerative colitis for at least 6 months.~* Patient with mayo endoscopic score ≥ 1~* Patient with mild to moderate disease activity (3 \< SCCI \< 12)~* Ongoing treatment by mesalamine, steroids, thiopurines or Tumor Necrosis Factor antagonist at stable dose.~* Patients who have given written informed consent.~Exclusion Criteria:~* Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.~* Psychiatric disease that alter the judgment~* Stoma~* Proctocolectomy~* Severe disease (SCCI \>12, acute severe colitis)~* Steroid dose \> 10 mg/j or introduction of steroid (topic or oral) within 4 weeks~* Introduction or dose optimization of TNF antagonist within 4 months~* Introduction or dose optimization of thiopurine~* Hemoglobin level \< 11,5 g/dL, Platelets \> 400000/mm3, Leukocytosis \> 10 000/mm3~* Intolerant to lactose~* Disease extent limited to the rectum~* Mayo endoscopic subscore of 3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotics (Type: EXPERIMENTAL): Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).